Clinical Trials | April 22, 2026
Ultomiris shows strong interim results in Phase III IgA nephropathy trial
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
